Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment-Reference-Cited by-同舟云学术

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Published:2022-11-09 Issue:670 Volume:14 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kirchhammer Nicole¹^ORCID,Trefny Marcel P.¹^ORCID,Auf der Maur Priska²^ORCID,Läubli Heinz³⁴^ORCID,Zippelius Alfred¹⁴^ORCID

Affiliation:

1. Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.

2. Tumor Heterogeneity, Metastasis and Resistance, Department of Biomedicine, University and University Hospital of Basel, Basel 4031, Switzerland.

3. Cancer Immunotherapy, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.

4. Medical Oncology, University Hospital Basel, Basel 4031, Switzerland.

Abstract

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference74 articles.

1. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

2. Next generation of immune checkpoint inhibitors and beyond

3. The tumor microenvironment

4. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

5. Turning cold tumors into hot tumors by improving T-cell infiltration

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered nano-aluminum adjuvant for cancer immunotherapy: Progress, challenges and opportunities towards preclinical/clinical application;Coordination Chemistry Reviews;2024-11

2. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy;Chemical Engineering Journal;2024-10

3. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges;Acta Pharmaceutica Sinica B;2024-09

4. Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity;Journal of Lipid Research;2024-09

5. A GSH‐Responsive Immune‐Stimulating Polypeptide Hydrogel Loaded with Chemotherapeutics, IDO Inhibitor and Immune Checkpoint Blocking Antibody for Enhanced Anti‐Tumor Chemo‐Immunotherapy;Chinese Journal of Chemistry;2024-08-08